PharmaCyte Biotech Releases Shareholder Call and Complete Q&A Playback Information
February 08 2017 - 9:00AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing therapies for cancer
and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that an audio recording
of the company’s shareholder call, which was held on February 7,
2017, by the Chief Executive Officer of PharmaCyte, Kenneth L.
Waggoner, is now available for playback. PharmaCyte also announced
that the remaining unanswered questions and answers have been
recorded and are available playback as well.
Mr. Waggoner commented on the shareholder call stating, “I would
like to thank everyone who listened to our shareholder call update
yesterday. I would also like to apologize for the call abruptly
cutting off during the question and answer session. The call
stopped at the one-hour mark. That has never happened before. The
call was scheduled to continue for one and a half hours. Since we
wanted to answer all of the questions that were submitted, we have
recorded the balance of the questions and answers. They may be
heard by clicking on the second link shown below.”
To access the audio recording of the shareholder
call, use this link: https://fccdl.in/NYOkZc1xs.
To access the audio recording with the remaining
questions and answers of the shareholder call, use this link:
https://fccdl.in/b0lcv21IV.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage
biotechnology company developing therapies for cancer and diabetes
based upon a proprietary cellulose-based live cell encapsulation
technology known as “Cell-in-a-Box®.” This technology will be used
as a platform upon which therapies for several types of cancer and
diabetes are being developed. PharmaCyte’s therapy for cancer
involves encapsulating genetically engineered human cells that
convert an inactive chemotherapy drug into its active or
“cancer-killing” form. These encapsulated cells are implanted as
close to the patient’s cancerous tumor as possible. Once
implanted, a chemotherapy drug that is normally activated in the
liver (ifosfamide) is given intravenously at one-third the normal
dose. The ifosfamide is carried by the circulatory system to where
the encapsulated cells have been implanted. When the ifosfamide
comes in contact with the encapsulated cells they act as an
artificial liver and activate the chemotherapy drug at the source
of the cancer. This “targeted chemotherapy” has proven effective
and safe to use in past clinical trials and results in no side
effects.
In addition to developing a novel therapy for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and insulin-dependent Type 2 diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology. Once the encapsulated cells are
implanted in a diabetic patient they will function as a
“bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
"expects," "anticipates," "believes," "intends," "estimates,"
"plans," "will," "outlook" and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
risk factors, many of which are discussed in more detail in our
Annual Report on Form 10-K and our other reports filed with the
Securities and Exchange Commission.
More information about PharmaCyte can be found
at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: Info@PharmaCyte.com